Alk-Abello AS (AKBLF)
22.05
0.00 (0.00%)
USD |
OTCM |
Nov 21, 16:00
Alk-Abello Enterprise Value: 4.827B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 4.827B |
| November 20, 2024 | 4.827B |
| November 19, 2024 | 4.827B |
| November 18, 2024 | 4.827B |
| November 15, 2024 | 4.827B |
| November 14, 2024 | 4.948B |
| November 13, 2024 | 5.214B |
| November 12, 2024 | 5.214B |
| November 11, 2024 | 5.369B |
| November 08, 2024 | 5.259B |
| November 07, 2024 | 5.259B |
| November 06, 2024 | 5.259B |
| November 05, 2024 | 5.259B |
| November 04, 2024 | 5.259B |
| November 01, 2024 | 5.259B |
| October 31, 2024 | 5.259B |
| October 30, 2024 | 5.259B |
| October 29, 2024 | 5.259B |
| October 28, 2024 | 5.507B |
| October 25, 2024 | 5.507B |
| October 24, 2024 | 5.507B |
| October 23, 2024 | 5.507B |
| October 22, 2024 | 5.507B |
| October 21, 2024 | 5.507B |
| October 18, 2024 | 5.507B |
| Date | Value |
|---|---|
| October 17, 2024 | 5.507B |
| October 16, 2024 | 5.507B |
| October 15, 2024 | 5.507B |
| October 14, 2024 | 5.812B |
| October 11, 2024 | 5.812B |
| October 10, 2024 | 5.812B |
| October 09, 2024 | 5.812B |
| October 08, 2024 | 5.812B |
| October 07, 2024 | 5.812B |
| October 04, 2024 | 5.812B |
| October 03, 2024 | 5.812B |
| October 02, 2024 | 5.812B |
| October 01, 2024 | 5.812B |
| September 30, 2024 | 5.812B |
| September 27, 2024 | 5.951B |
| September 26, 2024 | 5.951B |
| September 25, 2024 | 5.951B |
| September 24, 2024 | 5.951B |
| September 23, 2024 | 5.951B |
| September 20, 2024 | 5.951B |
| September 19, 2024 | 5.412B |
| September 18, 2024 | 5.412B |
| September 17, 2024 | 5.412B |
| September 16, 2024 | 5.412B |
| September 13, 2024 | 5.412B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.967B
Minimum
Jul 07 2023
5.951B
Maximum
Sep 20 2024
3.785B
Average
3.949B
Median
Apr 19 2024
Enterprise Value Benchmarks
| Genmab AS | 10.41B |
| Ascendis Pharma AS | 7.511B |
| Galecto Inc | -11.98M |
| Evaxion Biotech AS | 3.461M |
| IO Biotech Inc | -35.25M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 31.24M |
| Revenue (Quarterly) | 193.50M |
| Total Expenses (Quarterly) | 148.40M |
| EPS Diluted (Quarterly) | 0.1474 |
| Gross Profit Margin (Quarterly) | 64.13% |
| Profit Margin (Quarterly) | 16.15% |
| Earnings Yield | 2.38% |
| Operating Earnings Yield | 3.23% |
| Normalized Earnings Yield | 2.377 |